Clinical Trial Update: Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating 24 weeks of oral BIIL 284 BS in adults and pediatric cystic fibrosis patients reported on efficacy and safety; the trial was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• BIIL 284 BS

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Cystic Fibrosis | Phase 2 | Status: TERMINATED